Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was $9.45 for the day, down -1.56% from the previous closing price of $9.6. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 0.85 million shares were traded. DAWN stock price reached its highest trading level at $9.65 during the session, while it also had its lowest trading level at $9.44.
Ratios:
Our analysis of DAWN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.68. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On October 09, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $32 to $33. BofA Securities Upgraded its Underperform to Buy on August 01, 2024, whereas the target price for the stock was revised from $11 to $24.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when Dubow Adam sold 4,319 shares for $8.91 per share. The transaction valued at 38,503 led to the insider holds 62,626 shares of the business.
York Charles N II sold 4,062 shares of DAWN for $36,212 on Nov 17 ’25. The COO and CFO now owns 294,715 shares after completing the transaction at $8.91 per share. On Nov 17 ’25, another insider, Merendino Lauren, who serves as the Chief Commercial Officer of the company, sold 3,726 shares for $8.91 each. As a result, the insider received 33,216 and left with 50,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 970283520 and an Enterprise Value of 521596480. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.26 while its Price-to-Book (P/B) ratio in mrq is 2.15. Its current Enterprise Value per Revenue stands at 3.902 whereas that against EBITDA is -3.212.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.28, which has changed by -0.24880761 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $13.53, while it has fallen to a 52-week low of $5.64. The 50-Day Moving Average of the stock is 11.03%, while the 200-Day Moving Average is calculated to be 27.61%.
Shares Statistics:
DAWN traded an average of 2.50M shares per day over the past three months and 3049850 shares per day over the past ten days. A total of 102.68M shares are outstanding, with a floating share count of 73.65M. Insiders hold about 28.27% of the company’s shares, while institutions hold 72.19% stake in the company. Shares short for DAWN as of 1765756800 were 9374807 with a Short Ratio of 3.75, compared to 1763078400 on 8969860. Therefore, it implies a Short% of Shares Outstanding of 9374807 and a Short% of Float of 13.5.
Earnings Estimates
The dynamic stock of Day One Biopharmaceuticals Inc (DAWN) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.62 and -$1.2 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$0.65, with 8.0 analysts recommending between -$0.07 and -$1.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $46.7M to a low estimate of $37.54M. As of. The current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $29.2MFor the next quarter, 9 analysts are estimating revenue of $50.86M. There is a high estimate of $54.1M for the next quarter, whereas the lowest estimate is $47.8M.
A total of 10 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151.2M, while the lowest revenue estimate was $142M, resulting in an average revenue estimate of $148.51M. In the same quarter a year ago, actual revenue was $131.16MBased on 10 analysts’ estimates, the company’s revenue will be $222.81M in the next fiscal year. The high estimate is $295M and the low estimate is $165.99M.
